English | Español

Novartis
+ Regulatory
Patient Daily | May 7, 2023

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa
+ Community
Patient Daily | May 7, 2023

Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
+ Technology/Innovation
Patient Daily | May 7, 2023

Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
+ Regulatory
Patient Daily | May 7, 2023

Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
+ Community
Carol Ostrow | Feb 7, 2019

Novartis says Cosentyx better at clearing skin in psoriasis patients than Stelara
+ Technology/Innovation
Press release submission | Dec 5, 2018

NOVARTIS: Announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
+ Technology/Innovation
Press releases submission | May 15, 2018

NOVARTIS: Alcon Cares Project 100 Commits to Reducing Cataract Blindness Globally
+ Regulatory
Carrie Bradon | Dec 1, 2017

Novartis announces positive results of MONALEESA-7 trial

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes